ArticleJournal of tissue engineering
Design of an artificial natural killer cell mimicking system to target tumour cells.
Article in Journal of tissue engineering. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NK cell mimics are assemblies of a cell membrane and a template that replicate biomimetic features and physicochemical properties, respectively. To develop this targeted drug delivery system, gelatin microspheres (cG) were fabricated using a water-in-oil emulsion and reinforced via DMTMM cross-linking to exhibit tunable Young's modulus, a critical parameter for cell-material interactions. These microspheres were subsequently coated with membranes derived from the human NK cell line KHYG-1 to form biomimetic NK cell mimics (cGCM), combining physicochemical control with bioinspired functionality. These engineered cGCM were non-toxic, non-inflammatory, and capable of reducing macrophage uptake by ~10% when incubated with differentiated THP-1 cells. In vitro studies demonstrated significant interaction/ proximity of the cGCM with cancer cells in 2D cultures of breast cancer cells (MDA-MB-231), 3D spheroids of liver (HepG2), and colon (HT-29) cancer cell models, and a zebrafish breast cancer xenograft (MDA-MB-231) model. The cGCM also evaded macrophage detection in a Kdrl:EGFP Spil:Ds Red zebrafish model. Furthermore, in a pilot assessment, loading and release of the sialyltransferase inhibitor (STI, 3Fax-Peracetyl Neu5Ac) using cGCM significantly reduced α-2,6 sialylation in 2D cultures of MDA-MB-231 cells, demonstrating the STI's intact functionality in inhibiting sialylation. By integrating bioinspired membranes with mechanically tunable gelatin-based carriers, our system demonstrates a multifunctional immune-mimicking platform with relevance to tissue engineering, tumour modelling, immune modulation, and drug delivery. These findings offer a promising foundation for future therapeutic strategies in cancer research and immuno-engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.